DelveInsight’s, “Metastatic Prostate Cancer Pipeline Insights 2026” report provides comprehensive insights about 80+ companies and 85+ pipeline drugs in Metastatic Prostate Cancer pipeline landscape. It covers the Metastatic Prostate Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Prostate Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Metastatic Prostate Cancer Pipeline. Dive into DelveInsight’s comprehensive report today! @ Metastatic Prostate Cancer Pipeline Outlook
Key Takeaways from the Metastatic Prostate Cancer Pipeline Report
- On March 19, 2026- Aragon Pharmaceuticals Inc. announced a study is to compare the radiographic progression-free survival (rPFS) of apalutamide in combination with abiraterone acetate (AA) plus prednisone or prednisolone (AAP) and AAP in participants with chemotherapy-naive (participants who did not receive any chemotherapy [treatment of cancer using drugs]) metastatic castration-resistant prostate cancer (mCRPC) (cancer of prostate gland [gland that makes fluid that aids movement of sperm]).
- On March 16, 2026- Janssen Research & Development LLC initiated a phase IV study is to compare the improvement in time to prostate specific antigen (PSA) progression (TTPP, as defined by Prostate Cancer Working Group 2 [PCWG2]) of apalutamide versus placebo in Chinese participants with high-risk non-metastatic castration resistant prostate cancer (NM-CRPC).
- On March 16, 2026- T.O.A.D. Oncology SA initiated a phase 1/2 study will evaluate the safety, tolerability, drug levels (pharmacokinetics) and preliminary antitumor activity of TD001, an antibody-drug conjugate (ADC) targeting prostate-specific membrane antigen (PSMA), in men with metastatic PSMA-expressing castration-resistant prostate cancer (CRPC).
- On March 16, 2026- Merck Sharp & Dohme LLC initiated a phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)
- On March 06, 2026- AstraZeneca conducted a Phase I/IIa study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer agents for treatment of metastatic prostate cancer.
- On March 02, 2026- Novartis Pharmaceuticals initiated a phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617) compared with AAA617 (control) in participants with metastatic Castration Resistant Prostate Cancer (mCRPC) with prior exposure to at least 1 Androgen Receptor Pathway Inhibitor (ARPI) and 0-2 taxane regimens and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and pharmacokinetic (PK) data from participants randomized in the study will be evaluated.
- DelveInsight’s Metastatic Prostate Cancer Pipeline report depicts a robust space with 80+ active players working to develop 85+ pipeline therapies for Metastatic Prostate Cancer treatment.
- The leading Metastatic Prostate Cancer Companies such as Merck, AstraZeneca, Syntrix Pharmaceuticals, Cardiff Oncology, Janux Therapeutics, ORIC Pharmaceuticals, Inc, Lantheus, Eli Lilly and Company, Madison Vaccines, Exelixis, Laekna Therapeutics, Regeneron Pharmaceuticals, Zenith Epigenetics, Phosplatin Therapeutics, MacroGenics, Modra Pharmaceuticals, RedHill Biopharma, DexTech Medical, Debiopharm, Astellas Pharma, Arvinas, Orion Corporation, CellCentric, Karyopharm Therapeutics, Corcept Therapeutics, OncoC4, Inmune Bio, Celcuity and others.
- Promising Metastatic Prostate Cancer Pipeline Therapies such as Enzalutamide, Cabazitaxel, Ifinatamab Deruxtecan, MK-5684, Aflibercept, HLD-0915, Prednisone, Quinacrine, SR31747A anad others.
Stay ahead with the most recent pipeline outlook for Metastatic Prostate Cancer @ Metastatic Prostate Cancer Treatment Drugs
Metastatic Hormone Refractory Prostate Cancer Overview
Metastatic Hormone-Refractory Prostate Cancer (mHRPC), also known as metastatic castration-resistant prostate cancer (mCRPC), is an advanced stage of prostate cancer in which the disease continues to progress despite the suppression of testosterone to castrate levels. Initially, prostate cancer growth is typically driven by androgens, and hormone therapy is effective in slowing or stopping the disease. However, in mHRPC, cancer cells adapt and continue to grow even in the low-androgen environment. The cancer has also spread beyond the prostate gland to distant sites, most commonly bones and lymph nodes. This stage is associated with more aggressive behavior, increased symptom burden, and limited treatment options, requiring systemic therapies aimed at prolonging survival and improving quality of life.
Metastatic Prostate Cancer Emerging Drugs Profile
- Opevesostat: Merck
Opevesostat is an oral, non-steroidal and selective inhibitor of the CYP11A1 enzyme discovered and developed by Orion for the treatment of hormone-dependent cancers, such as prostate cancer. By inhibiting CYP11A1 enzyme activity, ODM-208 is designed to suppress the production of all steroid hormones and their precursors that may activate the androgen receptor signaling pathway. Currently, the drug is in Phase III stage of its development for the treatment of Metastatic Prostate Cancer.
- AZD5305: AstraZeneca
AZD5305 is a highly potent and selective inhibitor of PARP1 with 500-fold selectivity for PARP1 over PARP2. When PARP1 is inhibited, it leads to the accumulation of DNA damage, particularly in cells lacking functional HRR pathways. This results in cell death due to the inability to repair critical DNA lesions. AZD5305 inhibits growth in cells with deficiencies in DNA repair, with minimal/no effects in other cells. Currently, the drug is in Phase III stage of its development for the treatment of Metastatic Prostate Cancer.
- SX-682: Syntrix Pharmaceuticals
SX-682 is a potent small-molecule dual-inhibitor of CXCR1 and CXCR2, chemokine receptors pivotal to myeloid cell suppression of cancer surveillance by the adaptive immune system. By blocking the CXCR1/2 pathway, SX-682 inactivates immunosuppressive myeloid cells, thereby cutting off “at the source” dozens of downstream pro-tumor mechanisms mediated by these cells. The inactivation of suppressive myeloid cells liberates effector cells to kill and eliminate cancer cells. Currently, the drug is in Phase II stage of its development for the treatment of Metastatic Prostate Cancer.
- Onvansertib: Cardiff Oncology
Onvansertib is a first-in-class, third generation, highly selective, oral Polo like Kinase 1 (PLK1) inhibitor, that is designed to target and inhibit cancer cell division (mitosis). It is an orally bioavailable, adenosine triphosphate (ATP) competitive inhibitor of polo-like kinase 1 (PLK1; PLK-1; STPK13), with potential antineoplastic activity. Upon administration, Onvansertib selectively binds to and inhibits PLK1, which disrupts mitosis and induces selective G2/M cell-cycle arrest followed by apoptosis in PLK1-overexpressing tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase that is crucial for the regulation of mitosis, and plays a key role in tumor cell proliferation. PLK1 expression is upregulated in a variety of tumor cell types and high expression is associated with increased aggressiveness and poor prognosis. Currently, the drug is in Phase II stage of its development for the treatment of Metastatic Prostate Cancer.
- JANX007: Janux Therapeutics
JANX007 is lead novel Tumor Activated T Cell Engager (TRACTr). JANX007 is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of tumors and is in the clinic for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The company designed PSMA-TRACTr drug candidate as a single-masked TRACTr in which the PSMA-binding domain is unmasked. The T cell-specific binding domain (CD3e) is masked to help minimize CRS. Currently, the drug is in Phase I stage of its development for the treatment of Metastatic Prostate Cancer.
- ORIC-944: ORIC Pharmaceuticals, Inc
ORIC-944 is a potent and selective allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the embryonic ectoderm development (EED) subunit that demonstrates best-in-class drug properties in preclinical studies, including potency, solubility, and pharmacokinetics, with half-life supporting once daily dosing. ORIC-944 was initially evaluated as a single agent in a Phase Ib trial in patients with advanced prostate cancer and demonstrated potential best-in-class drug properties, including clinical half-life of approximately 20 hours, robust target engagement and a favorable safety profile. Currently, the drug is in Phase I stage of its development for the treatment of Metastatic Prostate Cancer.
The Metastatic Prostate Cancer Pipeline Report Provides Insights into-
- The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Prostate Cancer with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Prostate Cancer Treatment.
- Metastatic Prostate Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Metastatic Prostate Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Prostate Cancer market
Explore groundbreaking therapies and clinical trials in the Metastatic Prostate Cancer Pipeline @ New Metastatic Prostate Cancer Drugs
Metastatic Prostate Cancer Companies
Merck, AstraZeneca, Syntrix Pharmaceuticals, Cardiff Oncology, Janux Therapeutics, ORIC Pharmaceuticals, Inc, Lantheus, Eli Lilly and Company, Madison Vaccines, Exelixis, Laekna Therapeutics, Regeneron Pharmaceuticals, Zenith Epigenetics, Phosplatin Therapeutics, MacroGenics, Modra Pharmaceuticals, RedHill Biopharma, DexTech Medical, Debiopharm, Astellas Pharma, Arvinas, Orion Corporation, CellCentric, Karyopharm Therapeutics, Corcept Therapeutics, OncoC4, Inmune Bio, Celcuity and others.
Metastatic Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Metastatic Prostate Cancer Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Metastatic Prostate Cancer Market Drivers and Barriers
Scope of the Metastatic Prostate Cancer Pipeline Report
- Coverage- Global
- Metastatic Prostate Cancer Companies- Merck, AstraZeneca, Syntrix Pharmaceuticals, Cardiff Oncology, Janux Therapeutics, ORIC Pharmaceuticals, Inc, Lantheus, Eli Lilly and Company, Madison Vaccines, Exelixis, Laekna Therapeutics, Regeneron Pharmaceuticals, Zenith Epigenetics, Phosplatin Therapeutics, MacroGenics, Modra Pharmaceuticals, RedHill Biopharma, DexTech Medical, Debiopharm, Astellas Pharma, Arvinas, Orion Corporation, CellCentric, Karyopharm Therapeutics, Corcept Therapeutics, OncoC4, Inmune Bio, Celcuity and others.
- Metastatic Prostate Cancer Pipeline Therapies- Enzalutamide, Cabazitaxel, Ifinatamab Deruxtecan, MK-5684, Aflibercept, HLD-0915, Prednisone, Quinacrine, SR31747A anad others.
- Metastatic Prostate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Metastatic Prostate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Metastatic Prostate Cancer Pipeline Therapies and clinical trials @ Metastatic Prostate Cancer Companies, Key Products and Unmet Needs
Table of Contents
- Introduction
- Executive Summary
- Metastatic Prostate Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Metastatic Prostate Cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Opevesostat: Merck
- Mid Stage Products (Phase II)
- SX-682: Syntrix Pharmaceuticals
- Early Stage Products (Phase I)
- JANX007: Janux Therapeutics
- Preclinical and Discovery Stage Products
- Drug Name: Company Name
- Inactive Products
- Metastatic Prostate Cancer Key Companies
- Metastatic Prostate Cancer Key Products
- Metastatic Prostate Cancer- Unmet Needs
- Metastatic Prostate Cancer- Market Drivers and Barriers
- Metastatic Prostate Cancer- Future Perspectives and Conclusion
- Metastatic Prostate Cancer Analyst Views
- Metastatic Prostate Cancer Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-hormone-refractory-prostate-cancer-pipeline-insight